Fibrosis Scarring
Fibrosis Scarring - Related Videos
07:40
Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
0 Views •
2022
This protocol describes the generation of a skin-fascia explant termed "SCar like tissue in A Dish" or SCAD. This model allows unprecedented visualization of single fibroblasts during scar formation.
09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
0 Views •
Cited by 11 •
2016
We describe a method to produce an animal model of liver fibrosis in the rat, and assess the degree of fibrosis by histological examination of the liver. The model can be used to study the development of liver disease as well as to test the efficacy of potential anti-fibrotic agents.
05:54
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
0 Views •
Cited by 3 •
2024
This protocol will explain how to establish a hypertrophic scarring murine model that increases mechanotransduction signaling to simulate human-like scarring. This method involves increasing mechanical tension across a healing incision in a mouse and using a specialized device to create reproducible, excessive scar tissue for detailed histological and bioinformatic analyses.
01:23
Cystic Fibrosis: Pathogenesis
0 Views •
2024
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body. CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
0 Views •
Cited by 1 •
2025
Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.
FAQs
Repeated injury or persistent inflammation keeps tissue-repair pathways active instead of allowing them to resolve normally. This ongoing signaling activates fibroblasts and related cells, which increase production and deposition of extracellular matrix proteins, including collagen. Over time, continued matrix accumulation changes tissue architecture and can interfere with the function of the affected organ.
Fibrosis scarring progresses when extracellular matrix deposition exceeds matrix breakdown. Collagen and other connective tissue components therefore remain in the tissue rather than being adequately removed during remodeling. This imbalance allows scar material to accumulate, making the process persistent and increasing the likelihood that normal tissue will be replaced by less functional connective tissue.
Normal wound healing requires repair pathways that restore tissue while preserving appropriate structure and function. Pathological scarring occurs when those pathways remain active or matrix removal is inadequate. The distinction is clinically important because treatment must limit excessive scar formation without eliminating the repair mechanisms needed for normal healing after injury.
Fibroblasts and related repair pathways are central drivers of fibrosis scarring. After repeated injury or chronic inflammation, these cells promote production and deposition of extracellular matrix proteins such as collagen. The resulting change is not only increased connective tissue; it is also altered tissue organization, which can progressively compromise the performance of the involved organ.
Clinical evaluation focuses on diagnosis, staging, and monitoring of the scarring process. These goals help determine whether tissue remodeling is present, how far it has progressed, and whether organ function may be declining. Assessment is relevant across liver, lung, heart, kidney, and other diseases because fibrosis can advance toward persistent or irreversible dysfunction.
The consequences depend on which organ is affected. In the liver, lungs, heart, kidneys, and other tissues, accumulated scar material can disrupt the local structure required for normal function. Clinical management therefore uses knowledge of fibrosis to support organ-specific diagnosis, staging, monitoring, and treatment decisions rather than treating scarring as a uniform process.
Treatment aims to limit pathological scar accumulation and preserve the tissue’s capacity for normal repair. This balance matters because excessive connective tissue can replace healthy tissue and impair organ function, while completely suppressing repair would be undesirable. Monitoring also helps clinicians evaluate whether the process is progressing toward irreversible dysfunction or remaining controlled.
Fibrosis provides a framework for studying how persistent injury, inflammation, fibroblast activation, matrix deposition, and inadequate matrix breakdown interact over time. Research can use this framework to connect tissue remodeling with declining organ function and to investigate approaches that restrain pathological scarring while maintaining effective wound healing across multiple organ systems.